Trials / Active Not Recruiting
Active Not RecruitingNCT06497504
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 157 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bepirovirsen | Bepirovirsen will be administered. |
| DRUG | Placebo | Placebo will be administered. |
Timeline
- Start date
- 2024-09-17
- Primary completion
- 2027-04-22
- Completion
- 2027-04-22
- First posted
- 2024-07-11
- Last updated
- 2026-02-04
Locations
51 sites across 10 countries: United States, Argentina, Brazil, Canada, France, Italy, South Africa, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06497504. Inclusion in this directory is not an endorsement.